AH1 

AH1 is an immunodominant antigen derived from the gp70 product of an endogenous MuLV. AH1 behaves as the CTL-immunodominant epitope of CT26 colon carcinoma^[1][2].

1127.21

C₅₄H₇₀N₁₂O₁₅

181272-91-3

Solid

White to off-white

Ser-Pro-Ser-Tyr-Val-Tyr-His-Gln-Phe

SPSYVYHQF

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](C(C)C)C(N[C@H](C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)CC3=CN=CN3)=O)CC4=CC=C(C=C4)O)=O)=O)NC([C@H](CO)NC([C@H]5N(CCC5)C([C@@H](N)CO)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. M Toda, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999 Feb 10;10(3):385-93.  [Content Brief]

  [2]. Antonio Rosato, et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res. 2003 May 1;63(9):2158-63.  [Content Brief]